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Abstract
Current method to magnetically label cells using ferumoxides (Fe)-protamine (Pro) sulfate (FePro) is based on generating
FePro complexes in a serum free media that are then incubated overnight with cells for the efficient labeling. However, this
labeling technique requires long (.12–16 hours) incubation time and uses relatively high dose of Pro (5–6 mg/ml) that
makes large extracellular FePro complexes. These complexes can be difficult to clean with simple cell washes and may
create low signal intensity on T2* weighted MRI that is not desirable. The purpose of this study was to revise the current
labeling method by using low dose of Pro and adding Fe and Pro directly to the cells before generating any FePro
complexes. Human tumor glioma (U251) and human monocytic leukemia cell (THP-1) lines were used as model systems for
attached and suspension cell types, respectively and dose dependent (Fe 25 to 100 mg/ml and Pro 0.75 to 3 mg/ml) and time
dependent (2 to 48 h) labeling experiments were performed. Labeling efficiency and cell viability of these cells were
assessed. Prussian blue staining revealed that more than 95% of cells were labeled. Intracellular iron concentration in U251
cells reached ,30–35 pg-iron/cell at 24 h when labeled with 100 mg/ml of Fe and 3 mg/ml of Pro. However, comparable
labeling was observed after 4 h across the described FePro concentrations. Similarly, THP-1 cells achieved ,10 pg-iron/cell
at 48 h when labeled with 100 mg/ml of Fe and 3 mg/ml of Pro. Again, comparable labeling was observed after 4 h for the
described FePro concentrations. FePro labeling did not significantly affect cell viability. There was almost no extracellular
FePro complexes observed after simple cell washes. To validate and to determine the effectiveness of the revised technique,
human T-cells, human hematopoietic stem cells (hHSC), human bone marrow stromal cells (hMSC) and mouse neuronal
stem cells (mNSC C17.2) were labeled. Labeling for 4 hours using 100 mg/ml of Fe and 3 mg/ml of Pro resulted in very
efficient labeling of these cells, without impairing their viability and functional capability. The new technique with short
incubation time using 100 mg/ml of Fe and 3 mg/ml of Pro is effective in labeling cells for cellular MRI.
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Introduction
Current development of stem cell transplantation therapies and
the optimization of transplantation parameters require efficient
and non-invasive method for in vivo monitoring and trafficking of
transplanted cells. In vivo cell tracking can be accomplished by
using different imaging modalities, such as positron emission
tomography (PET), single photon emission-computed tomography
(SPECT) and magnetic resonance imaging (MRI). MRI is non-
invasive, offering high spatial and temporal resolution and
therefore is an excellent means for in vivo cell tracking. However,
translation to routine clinical application of MRI cell tracking
method is coupled to the availability of efficient cell labeling
reagent that is not toxic and is incorporated in labeled cell in
sufficient quantities for detection by MRI. Superparamagnetic
iron oxide nanoparticles (SPION), such as ferumoxides, are a class
of MRI contrast agents used for imaging pathology in the liver [1],
and have also been used as an ex vivo cell labeling agent for various
types of mammalian cells for in vivo cellular MRI. For example,
SPIONs have successfully been used for the labeling of cancer cells
[2], T cells [3], dendritic cells [4] and stem cells[5,6] and the
techniques used to labeled cells have been extensively studied
[7,8,9,10]. As previously reported, SPION labeling does not
exhibit adverse effects on cell physiology [11,12] and when
combined with natural product cationic transfection reagents it is
incorporated [8] intracellularly within endosomes [13]. Previously,
we have reported a novel method for generating magnetically
labeled cells that is based on combining ferumoxides and
protamine sulfate (FePro; both FDA approved agents being used
for off label indications) into SPION-transfection agent complex
[6,14]. Magnetically labeled cells can then be used as probes for
localizing and monitoring physiological and/or pathological
processes. However, the quantitative capacity of cellular MRI
strongly depends on the ability to efficiently label cells with SPION
and accurately quantify the intracellular incorporation of the iron
nanoparticle. We previously reported [6,14] a protocol based on
initially generating FePro complexes in serum free media for the
purpose of labeling and subsequently adding the complexes to the
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efficient cell labeling this procedure required relatively prolonged
incubation times and a relatively high dose of Pro (5–6 mg/ml)
that generated large (inner radius of 200–500 nm) FePro
complexes. These complexes were difficult to eliminate from the
media and the external surface of the cells with simple cell washes
and may create extra low signal intensity on MRI, when cells were
injected locally. These low signal intensities on MRI from
extracellular SPION complexes are not desirable in any studies
when monitoring the migration of labeled cells by MRI.
The purpose of this study was to revise the current FePro
labeling method and to determine if the use of a lower dose of Pro
and the direct addition (without pre-mixing) of Fe and Pro to the
cells is more efficacious than mixing the cells with pre-made FePro
complexes that are generated in a separate labeling step. For this
study, human glioma tumor cell line (U251) and human acute
monocytic leukemia cell line (THP-1) were used to optimize the
technique and served as model systems for attached and
suspension cell types, respectively. These cells were labeled with
three different ratio combinations of Ferumoxide (Fe) and
Protamine Sulfate (Pro): (1) 100 mg/ml Fe and 3 mg/ml Pro, (2)
50 mg/ml Fe and 1.5 mg/ml Pro and (3) 25 mg/ml Fe and
0.75 mg/ml Pro. After 2, 4, 24 and 48 hours the labeling efficiency
was determined by analyzing cell viability, intracellular iron
concentration, and the MRI detection threshold of the labeled
cells. The optimized labeling protocol was then used to label
human T-cells, hHSC, hMSC and mNSC C17.2) to determine the
effectiveness of the technique.
Materials and Methods
Ethics Statement
The use of human cord blood in this study was approved by a
Henry Ford Health System Institutional Review Board (IRB).
Written informed consent was obtained and the consent process
was maintained under IRB-approved security protocol using an
IRB-approved consent form and the process of consent.
FePro labeling of cells
Human glioma cells (U-251, ATCC, Rockville, MD) were
grown in T25 cell culture flask in Dulbecco’s modified eagle’s
medium (DMEM) supplemented with 10% Fetal Bovine Serum
(FBS) (Hyclone) until they reached 80% confluence. For the
labeling purposes, media was aspirated and without disrupting the
cellular monolayer cells were washed once with 16PBS and
covered with 2.5 ml of serum free RPMI 1640.
THP-1 cells (ATCC, Rockville, MD) were maintained in RPMI
1640 (Sigma, St. Louis, MO) supplemented with 10% FBS
(Hyclone) and 0.05 mM 2-mercaptoethanol (Chemicon). For the
purpose of labeling, THP-1 cells were suspended at the
concentration of 4610
6 cell/ml in serum free RPMI and plated
in 24 well plate cell culture dish, 0.5 ml per well.
Commercially available Fe (Feridex IV; Bayer-Schering
Pharma, Wayne, NJ, USA) was first added to the cells by directly
pipetting into the culture dish, immediately after which Pro
(American Pharmaceuticals Partners, Shaumburg, IL, USA) was
added in the same manner. Pro was supplied as 10 mg/ml of
stock solution and was freshly diluted to a concentration of 1 mg/
ml in distilled water at the time of use. Cells were labeled with the
following concentration combinations of FePro complex: (1)
100 mg/ml Fe and 3 mg/ml Pro, (2) 50 mg/ml Fe and 1.5 mg/ml
Pro and (3) 25 mg/ml Fe and 0.75 mg/ml Pro. After incubating the
cells in the presence of FePro complexes for 15 minutes at 37uC,
5% CO2, complete growth media was added (2.5 ml per flask for
U251 cells and 0.5 ml per well for THP-1 cells) and the labeling
procedure was further continued for 2, 4, 24 and 48 h at 37uC,
5% CO2. Upon labeling, cells were harvested and washed two
times with 16PBS. Suspension type cells (THP-1) were collected
by pipeting, while attached cells (U251) were harvested by
trypsinization. After the last wash, FePro labeled cells were used
for phantom preparation, viability and intracellular iron concen-
tration assay, electron microscopy preparation and microscopic
slides preparations for PB staining. A generalized flow chart for
labeling cells is shown in Table 1.
Trypan Blue viability assay
FePro labeled cells were suspended in 16 PBS at the
concentration of 1610
6/ml and mixed with 0.4% of trypan blue
dye at the 1:1 ratio. Ten ml of this mixture was loaded into
hemocytometer, after which cells were counted. Cells with an
intact membrane excluded the dye and were considered as live
cells. The percentage of live and dead cells was determined.
Intracellular Iron Quantification
Quantification of intracellular iron FePro labeled cells was
performed as previously described [14,15]. Briefly, after labeling
with FePro, cells were washed three times with 16PBS to dispose
of extracellular FePro. Triplicates of labeled and non-labeled cells
(3610
5 cells per 1.5 ml microfuge tube) were centrifuged at
3000 rpm for 5 minutes. After discarding the supernatants, cell
pellets were incubated at 110uC overnight (no cap on tubes). The
next day, iron was dissolved by adding 1 mL of 5 M hydrochloric
acid (HCl) to each tube and samples were further incubated at
60uC for 4 h. During this incubation step, tubes were capped to
prevent acid evaporation. Then, 0.5 ml of acid solution from each
Table 1. Basic procedure for FePro cell labelling.
step Suspension cell types Attached cell types
14 610
6 cells/ml in serum free media Cells at 80–90% confluence in serum free media
2 Add Fe and mix Add Fe and mix
3 Add Pro and mix Add Pro and mix
4 Incubate 15 minutes, 37uC, 5% CO2 Incubate 15 minutes, 37uC, 5% CO2
5 Add complete growth media to achieve 2610
6 cells/ml Add complete growth media in the volume equal to the one of serum free
media added at the first step of the procedure
6 Incubate for 4 h 37uC, 5% CO2 Incubate for 4 h 37uC, 5% CO2
7 Wash 3 times in 16PBS Wash 3 times in 16PBS
doi:10.1371/journal.pone.0005873.t001
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was read at 351 nm. The average absorbance value for each
sample was divided by the number of cells to determine the
average iron concentration per cell. Iron concentration was
determined using the standard curve obtained by plotting the
known iron concentration of several dilutions of iron vs.
absorbance.
Staining for intracellular iron and determining the
labeling efficiency
Aliquots of labeled and non-labeled control cells were
transferred to glass slides and fixed with 4% paraformaldehyde.
Prussian blue cellular staining was performed by incubating fixed
cells in a mixture of 4% potassium ferrocyanide and 3.7% HCl
(Perl reagent for PB staining) for 30 minutes. Slides were then
washed and cells counterstained with nuclear fast red. For
diaminobenzide (DAB) enhanced PB staining, the slides were
reacted with activated 0.014% DAB, containing 0.03% hydrogen
peroxide, for 10–15 minutes, washed 3 times with 16 PBS and
then counterstained with nuclear fast red. The cells were evaluated
by light microscopy and cells exhibiting blue intracellular particles
were considered PB positive and the percentage of positive cells
was determined within the four randomly selected fields of view.
Magnetic Resonance Imaging
To determine the optimal time required for FePro to effectively
label cells that can be detected by clinical MRI, phantoms
containing labeled and unlabeled cells were made. After labeling,
cells were washed 3 times in 16 PBS counted and placed into
NMR tubes (tubes with no magnetic effects) at the concentration
of 1610
6 cell in 1 ml of PBS. Cells were then mixed with 1 ml of
8% gelatin and quickly solidified in ice.
MRI of the cell gel phantoms was performed with a whole body
3 T (Signa Excite, GE Medical Systems, Milwaukee, WI) using
dedicated small animal coils (Doty scientific, Columbus, NC). Two
dimensional multi-echo T2*-weighted images were obtained to
create R2* maps (1/sec) and the parameters used to acquire T2*-
weighted images were: TR=600 ms, TE=10, 15, 20 and 30
using a 1286128 matrix, FOV=40 mm, and NEX=2. Effective
slice thickness was 1 mm for T2*-weighted images and 13 slices
were imaged for each tube. Based on voxel size there were
estimated 49 cells per voxel.
Image Processing and analysis
R2* maps were calculated from T2*-weighted images of the
tubes. To generate the maps, the MR images were exported as
DICOM images from 3 T to a personal computer. Image analysis
was performed using Eigentool software that has a comprehensive
set of functions for displaying, restoring, enhancing and analyzing
images [16,17]. T2* maps were calculated as the reciprocal of the
negative slope of the logarithms of the T2*-weighted images and
R2* maps were created by inverting T2* maps, respectively. Mean
R2* values were measured in minimum of 5 different slices within
a region of interest (ROI).
FePro labeling of CD133+ hHSCs, hMSCs, mNSC C17.2
and CD3+ T cells and functional assessment of labeled T
cells
To determine the effectiveness of the revised technique labeling
procedure was performed by utilizing hMSCs and mNSCs, and
hHSCs and sensitized T cells that underwent the same labeling
procedure and analyses as described for attached (U251) and
suspension type (THP-1) cells using 100 mg/ml of Fe and 3 mg/ml
of Pro for 4 h. Human MSCs (Cambrex, USA) were grown in T25
cell culture flask in DMEM supplemented with 10% FBS and were
labeled when they reached 80% confluence. Mouse NSC C17.2
(generated by Dr. Snyder’s group and kindly provided by
neurosurgery department at Cornell University) were grown in
T25 cell culture flask in DMEM supplemented with 10% FBS and
5% Horse serum and were used for labeling when they reached
80% confluence. CD 133+ hHSCs and T-cells were isolated from
human cord blood, with an IRB approved protocol, by Ficoll
gradient centrifugation followed by immunomagnetic MACSH
system (Miltenyi Biotec Inc, Auburn, CA) CD133+ and CD3+
selection, respectively. Isolated CD133+ HSCs were cultured as
previously described [18]. In brief, cells were cultured in Stemline
II medium (Sigma, St. Louis, MO, USA) containing 40 ng/ml
stem cell factor, 40 ng/ml FLT3, and 10 ng/ml thrombopoietin
(all from CellGenix, Antioch, IL, USA) for at least 5 days before
labeling, with the cell concentration kept at 1610
6/ml. Isolated
CD3
+ cells were cultured in the presence of IL-2 (10 ng/ml) for
24 h, after which cells were co-cultured with c-irradiated (35–
40 Gy) tumor primed dendritic cells (10:1 ratio). After 7 days of
co-culture, T cells proliferated and were subjected to FePro
labeling. After labeling, T cells were exposed to secondary
stimulation by co-culturing with c-irradiated tumor primed
dendritic cells (10:1 ratio). After 5 days of co-culture T cell
proliferation was analyzed by performing MTT (3-[4,5-di-
methylthiazol-2-yl] -2,5-diphenyl tetrazolium bromide) assay
(Roche Molecular Biochemicals). The absorbance of the formazan
product was measured at a wavelength of 570 nm with 750 nm
(subtracted) as reference.
Electron Microscopy
Electron microscopy analysis was performed on the cells that
were fixed with 3% gluteraldehyde according to our previously
reported protocol [13]. In brief, the collected cells were fixed with
3% gluteraldehyde, washed three times with 0.1 M sodium
cacodylate buffer, re-suspended in 10% warm agarose in a
microfuge tube and immediately centrifuged (at 6000–
10 000 rpm) to collect the cells at the bottom. Once the agarose
gel hardened, the tip of the microfuge tube was clipped off and the
agar removed out the top of the tube. The area with the cells was
cut out (usually at the tip of the agar) and then re-suspended in
0.1 M sodium cacodylate buffer until ready for processing. The
cell-agar pellet was placed in 2% osmium tetroxide in 0.1 M Na
cacodylate buffer for 2 h. The osmium was removed and cell-agar
pellet was washed three times with 0.1 M Na cacodylate buffer.
Cells were then fixed in 1% uranyl acetate in 0.1 N acetate buffer
overnight and then fixed in a Lynx automated processor (EMS,
Hatfield, PA, USA) with alcohol dehydration, propylene oxide
dehydration and through epon infiltration. After hardening in an
epon mold at 60uC overnight, the cell-agar pellets were sectioned
at 50–70 nm and mounted on copper grids. The grids were
stained in uranyl acetate or with uranyl acetate and lead citrate.
The specimens were imaged with a transmission electron
microscope.
Statistical analysis
Each experiment was performed at least two times and each
sample was tested in triplicate. Data are expressed as mean6SD.
Statistically significant difference was determined with one way
ANOVA analysis followed by Fisher’s PLSD post-hoc test, when
there were more than two groups. For analysis between two
groups student-t test was used. A value of p,0.05 was considered
significant.
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Labeling efficiency and intracellular iron concentration in
FePro labeled THP-1 and U251 cells
Qualitative analysis of FePro cellular uptake was performed on
microscopic slide preparations of labeled cells that were stained
with Prussian blue (PB). Representative bright light photomicro-
graphs of THP-1 and U251 cells labeled with 100 mg/ml of Fe and
3 mg/ml of Pro for 4 h are shown in Figure 1A and 1B,
respectively. Labeled cells exhibited abundant, heterogeneous
uptake of FePro complexes that appeared as blue granules inside
the cytoplasm on PB stained slides. Labeling efficiency analysis
revealed that more than 95% of the cells were positive for PB.
Electron microscopy (EM) analysis of U-251 cells labeled with
100 mg/ml of Fe and 3 mg/ml of Pro for 4 h, demonstrated the
presence of fine FePro granules attached to the cell membranes
and on their way to be macropinocytosed by the cells (Figure 1C
and 1D), as well as intracellularly incorporated SPION within
endosomes (Figure 1D). These data confirmed that 4 h time
point was sufficient for generating intra-cytoplasmic, endosomal,
iron oxide nanoparticle deposits (Figure 1B–D). In addition, EM
demonstrated a decrease in the amount of large FePro complexes
that accumulated extracellularly when we used our previously
published labeling technique [6,14] (Figure 1F–G). After labeling
with 100 mg/ml of Fe and 3 mg/ml of Pro, intracellular iron
concentration in U251 cells reached the maximum of ,35 pg-
iron/cell at 24 h time point. The highest iron concentrations in U-
251 cells labeled with 50 mg/ml of Fe and 1.5 mg/ml of Pro and
25 mg/ml of Fe and 0.75 mg/ml of Pro were observed between 4–
24 h after labeling (Figure 2A). After labeling U251 cells for 4 hrs
with 100 mg/ml of Fe and 3 mg/ml of Pro, these cells exhibited
significantly higher intracellular Fe concentrations compared to
non-labeled control cells or cells incubated with 25–50 mg/ml of
Fe and 0.75–1.5 mg/ml of Pro (p,0.05). In THP-1 cells the
highest intracellular Fe concentrations were observed at 48 h in
cells incubated with 100 mg/ml of Fe and 3 mg/ml of Pro or with
25 mg/ml of Fe and 0.75 mg/ml of Pro. THP-1 cells incubated
with 50 mg/ml of Fe and 1.5 mg/ml of Pro exhibited peak
intracellular Fe levels at 24 h time point. However, incubating
THP-1 cells for 4 h with 100 mg/ml of Fe and 3 mg/ml of Pro
resulted in significantly higher intracellular Fe concentrations
(p,0.05) compared to two other FePro concentrations used
(Figure 2B).
Cellular Viability in FePro labeled U251 and THP-1 cells
The viability of FePro labeled U-251 and THP-1 cells was
analyzed by trypan blue assay (Table 2). We observed no
significant differences in viability of the labeled U-251 and THP-1
cells at different time points and different labeling FePro
concentrations, when compared to corresponding, non-labeled,
controls.
MRI results
Analysis of R2* values (1/sec) created from T2* images of the
FePro labeled THP-1 and U-251 cell phantoms revealed
incubation time and FePro concentration dependent changes
(Figure 2C–D). Compared to unlabeled cell-phantoms, FePro
labeled cells exhibited significant (p,0.05) increase in R2* values
in all phantoms. For the FePro labeled U-251 cells this difference
was observed even after 2 hours of incubation with the lowest
concentration of Fe (25 mg/ml) and Pro (0.75 mg/ml) used.
However, in THP-1 cells using the same labeling conditions (2 h
incubation; 25 mg/ml of Fe and 0.75 mg/ml of Pro), the R2*
values were not significantly increased compared to that of
unlabeled cells. When compared among the incubation time, there
was no significant difference in R2* values of cell phantoms
between 4 and 24 hours of incubation within the respective
concentration of Fe and Pro in both cell types (except THP-1 50/
1.5 condition), indicating that 4 hours may be minimal and
optimal time required for efficient cell labeling of these cell lines.
In addition, the observed changes in R2* values corresponded to
the results obtained by measuring iron concentration at indicated
incubation time points (Figure 2A–B).
FePro labeling of CD3+ T cells and CD133+ hHSC
To assess the effectiveness and validate the short incubation
time-low FePro concentration revised technique in suspension type
cells, activated CD3+ T-cells and CD 133+ hHSC were incubated
with 100 mg/ml of Fe and 3 mg/ml of Pro for 4 h. T-cell
immunological stimulation, manifested as proliferative T-cell
response, was induced by co-culturing T-cells with c-irradiated
(35–40 Gy) tumor primed dendritic cells. After 7 days of co-
culture, T-cells were incubated with FePro and analyzed for
labeling efficiency, intracellular iron concentration and cell
viability. As expected labeling efficiency, assessed by DAB-
enhanced PB staining (Figure 3A–B) was greater than 95% and
electron microscopy analysis showed intracytoplasmic/endosomal
localization of internalized iron complexes (Figure 3C–D). In
addition, intracellular iron concentration was significantly
(p,0.05) higher compared to non-labeled, control T-cells
(4.3 pg/cell vs. 0.19 pg/cell). Trypan blue analysis showed that
the 4 hr incubation time labeling with FePro did not have any
significant effect on T-cell viability (53%), compared to non-
labeled control cells (55%). Most importantly, FePro labeled T-
cells exhibited significant proliferative response after secondary
immunological stimulation induced by 5 days co-culture with c-
irradiated tumor primed dendritic cells. This response, analyzed
by MTT assay and expressed as optical density, exhibited no
difference between labeled (0.27960.0015) and control, non-
labeled T-cells (0.26060.003). These data indicate that the 4 hour
incubation time and lower concentration of FePro in media did
not alter T-cell functional status.
Incubating of CD133+ hHSCs with 100 mg/ml of Fe and 3 mg/
ml of Pro for 4 h also resulted in efficient labeling with generating
expected intracytoplasmic/endosomal iron deposits (Figure 3E–
G). Intracellular iron concentration was significantly (p,0.05)
higher compared to non-labeled, control hHSCs (2.8 pg/cell
vs.0.7 pg/cell) and had no significant effect on cell viability
(p.0.05).
To validate the revised labeling technique in attached non-
cancerous cell types, hMSCs and mNSCs C17.2 were incubated
with 100 mg/ml of Fe and 3 mg/ml of Pro for 4 h. The presence of
SPION in endosomes was confirmed with PB and DAB enhanced
PB staining of hMSC (Figure 4A–C) and mNSCs (Figure 4D–
F) cytospin preparations. In addition, analysis of intracellular iron
concentration revealed the significant difference (p,0.05) between
labeled and non-labeled hMSCs (19.1 pg/cell vs. 5.1 pg/cell) and
between labeled and non-labeled mNSCs (10.1 pg/cell vs. 2.7 pg/
cell) with no effect on cell viability (data not shown). It is possible
that the higher basal levels of intracellular iron observed in non-
label cells are due to the relatively high content of Ferric nitrate
(0.1 mg/ml) in the complete media required for the growth of
these cells.
Discussion
The purpose of this study was to revise the current FePro
labeling method [6,14] based on initially generating FePro
FePro Cell Labeling Method
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culture media. Although this method usually generated excellent
cellular in vivo MRI probes, it needed the improvements due to
several drawbacks. For the efficient cell labeling this procedure
required relatively prolonged (i.e., .12 hours) incubation times
that may affect the cellular functional status. In addition, this
method used a relatively high dose of Pro (5–6 mg/ml) that
generated large FePro complexes that would attach to the outer
cellular surface that could remain extracellular. These complexes
were not always easy to eliminate from the media and the surface
Figure 1. FePro labeled THP-1 and U-251 cells. Microphotography of cells labeled with 100 mg/ml Fe and 3 mg/ml Pro for 4 h and stained using
PB method to visualize the intracellular iron incorporation in THP-1 cells (A, bar=50 mm) and U-251 cells (B, bar=50 mm). Electron microscopy
images of U251 cells labeled with 100 mg/ml Fe and 3 mg/ml Pro for 4 h (C, D, bar=1 mm) and control unlabeled U251 cells (E, bar=1 mm). Note;
extracellular FePro granules attached to the cell membranes and on their way to be engulfed and endocytosed (arrows) (C) and endocytosed
intracellular iron within the endosomal compartment (arrows in circles) (D). Very little to no extracellular particles of FePro complexes seen compared
to our previous method of labeling cells (F, G). Prussian blue staining of magnetically labeled hMSCs using our previous method showing
extracellular complexes (F, bar=10 mm) which are also confirmed by electron microscopic images (G bar=2 mm). Extracellular complexes pointed by
arrows in F–G.
doi:10.1371/journal.pone.0005873.g001
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often generate low signal intensity on MRI when cells were
injected locally or are taken up by local tissue macrophages
following direct implantation [19]. Hence, the low signal intensity
generated as a result of extracellular FePro complexes may impede
the accuracy of further quantitative MRI analysis.
In the present study, we have revised the current method and
demonstrated that the optimal incubation protocol for the efficient
labeling of adherent and suspension cells with FePro involve
concentration ratio of 100 mg/ml of Fe and 3 mg/ml of Pro and
the incubation time of 4 h at 37uC, 5% CO2. These conditions
allow for the labeling of greater than 95% of cells in culture with
Figure 2. Intracellular iron concentration and MRI analyses of THP-1 and U251 phantom preparations. Iron concentration in U251 (A)
and THP-1 (B) cells that were labeled with 100 mg/ml Fe and 3 mg/ml Pro (red), 50 mg/ml Fe and 1.5 mg/ml Pro (blue), and 25 mg/ml Fe and 0.75 mg/
ml Pro (green). Cells were incubated for 2, 4, 24 and 48 h at 37uC, 5% CO2. Non-labeled cells (black). Data expressed as means6SD. *p,0.05 for cells
labeled with 100 mg/ml Fe and 3 mg/ml Pro for 4 h vs. cells labeled with 0–50 mg/ml Fe and 0–1.5 mg/ml Pro. R2* values of U251 (C) and THP-1 (D)
cells labeled with 100 mg/ml Fe and 3 mg/ml Pro (star), 50 mg/ml Fe and 1.5 mg/ml Pro (square), and 25 mg/ml Fe and 0.75 mg/ml Pro (circle). Data
expressed as means6SD. *p,0.05 for unlabeled vs. labeled cells.
#p,0.05 THP-1 labeled with 50 mg/ml Fe and 1.5 mg/ml Pro for 4 h vs. THP-1
labeled with 50 mg/ml Fe and 1.5 mg/ml Pro for 24 h.
doi:10.1371/journal.pone.0005873.g002
Table 2. Percentage of viable THP-1 and U-251 cells at different time points after FePro labeling as assessed by Trypan blue
viability test.
25 Fe/0.7 Pro 50 Fe/1.5 Pro 100 Fe/3 Pro Non-labeled
THP-1 U-251 THP-1 U-251 THP-1 U-251 THP-1 U-251
2h 88.0% 83.3% 94.1% 86.1% 92.7% 86.6%
4h 90.0% 89.5% 94.7% 90.2% 92.0% 90.1%
24 h 94.7% 82.8% 94.2% 84.3% 90.0% 89.0% 93.5% 88.7%
48 h 94.0% 82.5% 92.0% 86.3% 89.6% 85.6%
doi:10.1371/journal.pone.0005873.t002
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concentration in U251 labeled with 100 mg/3 mg FePro reached
the peak at 24 h post labeling, elevated iron content levels were
already achieved at 2 and 4 h of incubation. At the same time,
the intracellular iron levels generated after incubating cells for
4 h with 100 mg/3 mg ratio of FePro were sufficient to create
significant increase in R2* values on MRI analysis of labeled
cells phantom preparations. In addition, MRI R2* values in
phantom preparations of attached and/or suspension cell types
were not significantly changed with increasing the concentration
or cellular exposure time to FePro in culture media. Electron
microscopy showed FePro located in endosomes without
extracellular aggregates indicating that the achieved MRI
detection threshold was due to the intracellularly incorporated
ferumoxides. Therefore intracellular Fe levels obtained at 4 hrs
were sufficient with regard to the MRI detection threshold in
phantoms, eliminating the need for longer FePro labeling
incubation time. Most importantly, validation experiments using
T cells, CD133+ hHSCs, hMSCs and mNSCs revealed that
incubating these cells for 4 h with 100 mg/ml of Fe and 3 mg/ml
of Pro achieved high labeling efficiency without impairing the
cellular viability. In addition, the functional properties of
immunological T cell activity were not affected by internalized
Fe complexes.
In conclusion, using the short incubation revised technique
(Table 1) we achieved very efficient cell labeling, without
impairing viability and functional capability that was successfully
detected by MRI. Therefore, the new technique with short
incubation time (4 h) using 100 mg/ml of Fe and 3 mg/ml of Pro
that are directly added to the cells, is effective in labeling cells for
cellular MRI. Importantly, this method holds enormous potential
to be translated from bench to bedside using clinical grade plastics
and materials in clinical good manufacturing practice facility. In
addition, our new method can also be used for cell labeling with
other commercially available SPIO nanoparticles that have similar
zeta potential, dextran coating and sizes. Currently, few
companies offer these similar SPIO nanoparticles available for
research [20,21,22].
Figure 3. FePro labeled T and AC133+ hHSCs cells. Microphotography DAB-enhanced PB staining of non-labeled T-cells (A, bar=50 mm) and T
cells labeled with 100 mg/ml Fe and 3 mg/ml Pro for 4 h (B, bar=50 mm). Note the intracellular localization of FePro complexes that appear as the
dark brown granules on electron microscopic images (arrows). Electron microscopy images of T-cells (C–D, bar=1 mm) and AC133+ HSCs (F–G,
bar=1 mm) cells labeled with 100 mg/ml Fe and 3 mg/ml Pro for 4 h. Prussian blue staining of AC133+ HSCs cells (E, bar=20 mm).
doi:10.1371/journal.pone.0005873.g003
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Figure 4. Unlabeled and FePro labeled hMSC (A–C) and mNSC (D–F) cells. Microphotography of PB staining of non-labeled (A) and PB (B)
and DAB-enhanced PB (C) staining of hMSC cells labeled with 100 mg/ml Fe and 3 mg/ml Pro for 4 h (B–C, show images taken from two different
fields in the same slide). PB staining of non-labeled (D) and PB (E) and DAB-enhanced PB (F) staining of mNSC cells labeled with 100 mg/ml Fe and
3 mg/ml Pro for 4 h. Note the intracellular localization of FePro complexes that appear as blue (PB stain) and the dark brown granules (DAB enhanced
PB stain). (A–F, bar=100 mm).
doi:10.1371/journal.pone.0005873.g004
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